Please provide your email address to receive an email when new articles are posted on . Vyznova received regulatory approval in Japan for the treatment of bullous keratopathy. Injectable endothelial ...
This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...
CLEVELAND - A new predictor of cornea transplant success has been identified by the Cornea Donor Study (CDS) Investigator Group. New analysis of data from the 2008 Specular Microscopy Ancillary Study ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The therapy, which was invented by Kinoshita, received ...
TOKYO--(BUSINESS WIRE)--Cellusion Inc. (CEO: Shin Hatou, M.D. Ph.D., "Cellusion") announced that our research collaborator, Dr. Shigeto Shimmura, Professor of Fujita Health University and Keio ...
Corneal transplantation using donor tissue is currently the primary treatment for corneal endothelial insufficiency. Despite the potential for vision restoration through corneal transplantation, there ...
Researchers at Harvard Medical School have demonstrated the potent therapeutic effects of administration of the neuropeptide α-melanocyte–stimulating hormone (α-MSH) through melanocortin receptor ...
Hazy vision is a symptom of corneal edema secondary to endothelial dysfunction. (Aurion Biotech Image) Aurion Biotech has raised $120 million to advance its cell therapy for an eye disorder that ...
Findings from a pioneering study in The American Journal of Pathology, published by Elsevier, reveal that administration of the neuropeptide α-melanocyte-stimulating hormone (α-MSH) promotes corneal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results